BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15782129)

  • 1. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
    Xie Q; Gao CF; Shinomiya N; Sausville E; Hay R; Gustafson M; Shen Y; Wenkert D; Vande Woude GF
    Oncogene; 2005 May; 24(23):3697-707. PubMed ID: 15782129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K; Kijowski J; SekuĊ‚a M; Majka M
    Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of junction assembly in cultured epithelial cells by hepatocyte growth factor/scatter factor is concomitant with increased stability and altered phosphorylation of the soluble junctional molecules.
    Pasdar M; Li Z; Marreli M; Nguyen BT; Park M; Wong K
    Cell Growth Differ; 1997 Apr; 8(4):451-62. PubMed ID: 9101091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
    Besser D; Bardelli A; Didichenko S; Thelen M; Comoglio PM; Ponzetto C; Nagamine Y
    Oncogene; 1997 Feb; 14(6):705-11. PubMed ID: 9038378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.
    Shen Y; Xie Q; Norberg M; Sausville E; Vande Woude G; Wenkert D
    Bioorg Med Chem; 2005 Aug; 13(16):4960-71. PubMed ID: 15978816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells.
    Koga F; Tsutsumi S; Neckers LM
    Cell Cycle; 2007 Jun; 6(11):1393-402. PubMed ID: 17525527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics of HGF-SF and its role in cell motility and invasion.
    Weidner KM; Hartmann G; Naldini L; Comoglio PM; Sachs M; Fonatsch C; Rieder H; Birchmeier W
    EXS; 1993; 65():311-28. PubMed ID: 8380739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.
    Date K; Matsumoto K; Kuba K; Shimura H; Tanaka M; Nakamura T
    Oncogene; 1998 Dec; 17(23):3045-54. PubMed ID: 9881707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
    Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
    J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
    Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
    Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
    Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
    Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
    Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.
    Zhang YW; Su Y; Lanning N; Gustafson M; Shinomiya N; Zhao P; Cao B; Tsarfaty G; Wang LM; Hay R; Vande Woude GF
    Oncogene; 2005 Jan; 24(1):101-6. PubMed ID: 15531925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways.
    Leibowitz-Amit R; Tsarfaty G; Abargil Y; Yerushalmi GM; Horev J; Tsarfaty I
    Cancer Res; 2006 Sep; 66(17):8687-97. PubMed ID: 16951184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.